Пульс - медицинский центр 
Пульс - медицинский центр
Круглосуточно
бесплатно по России
+7 (965) 177 17 74
бесплатно по России
Regardless of the period of the life cycle, it is necessary to increase self-esteem of health by optimizing the social environment, introducing the basics of a healthy lifestyle (in particular, various forms of self-realization, regular physical education and sports of optimal intensity, fitness, yoga, etc.). After all, inadequate self-assessment of one's own health can change a person's behavior in a negative direction, lead to the health of destructive or deviant forms of behavior.
Сульфасалазин и 5-аминосалицилат Препараты 5-АСК обладают очень слабой иммуносупрессивной активностью. Нет сообщений о том, что эти препараты связаны с повышенным риском инфицирования, а исследования, оценивающие профиль безопасности 5-АСК, не демонстрируют повышенного риска серьезных или оппортунистических инфекций. Лечение 5-АСК следует продолжать, не беспокоясь о повышенном риске заражения или развития тяжелой формы COVID-19 . Если пациент находится в контакте с больным COVID-19 или у него развивается COVID-19, лечение 5-АСК следует продолжить.
Responding to such epidemic challenges is very difficult both organizationally and financially. The result is evaluated over time with well-organized epidemiological surveillance. According to the approved polio outbreak response plan, which arose in early October 2021, it was only possible to start the 1st round of the campaign on February 1, 2022. It was supposed to last 3 weeks and was aimed at vaccinating 140,000 children from 6 months of age with IPV. up to 6 years who missed vaccination according to the Calendar. Almost by the end of the 3rd week of the 1st round, as of February 18, 2022, only 28% of the planned number of children were vaccinated. Therefore, we decided to extend the 1st round for an additional 2 weeks, which again was not performed due to the outbreak of war. Thus, there was no actual response to polio outbreaks.
5-ASA preparations have very weak immunosuppressive activity. There are no reports that these drugs are associated with an increased risk of infection, and studies evaluating the safety profile of 5-ASA do not show an increased risk of serious or opportunistic infections. Treatment with 5-ASA should be continued without concern for an increased risk of infection or severe COVID-19. If the patient is in contact with a patient with COVID-19 or develops COVID-19, treatment with 5-ASA should be continued.
Закажите обратный звонок
Задать вопрос
Быстрая запись на прием